Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Marvell Technology, Inc. (MRV.TO)
Mississauga, ON, CA
Nuvo Pharmaceuticals Inc., operating globally as Miravo Healthcare, specializes in developing and distributing a diverse portfolio of prescription and non-prescription medical solutions, addressing conditions across pain management, allergies, neurology, and dermatology. Its business model is segmented into three core areas: Commercial sales, Production and Service, and a Licensing and Royalty framework. The company's extensive product portfolio encompasses Blexten, an antihistamine for allergic rhinitis and chronic urticaria, alongside migraine treatments such as the NSAID Cambia and Suvexx/Treximet. For pain and musculoskeletal health, offerings include NeoVisc, an injectable viscosupplement for osteoarthritis; the topical Pennsaid and Pennsaid 2% for osteoarthritic pain; and Vimovo for broader arthritis symptom relief. It also tackles head lice infestations with products such as Resultz, FullMarks, and LAUSBUB, and provides Soriatane for psoriasis and other keratinization disorders. Further extending its therapeutic reach are Bezalip SR for high cholesterol and triglyceride levels, Proferrin as an iron supplement, Fiorinal for tension-type headaches, Collatamp G for surgical implantation, PegaLAX and Mutaflor for gastrointestinal regularity, and MoviPrep for colon preparation. The portfolio is completed by SYNERA and RAPYDAN topical patches, along with the Heated Lidocaine/Tetracaine Patch, all purposed to alleviate pain during medical procedures, in addition to Yosprala for preventing cardiovascular events. Initially incorporated in 1983 as Nuvo Research Inc., the company rebranded as Nuvo Pharmaceuticals Inc. in March 2016. Its corporate headquarters are situated in Mississauga, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.07% | -2.68% | +58.26% | +74.14% | +74.14% | +74.14% | +74.14% | +74.14% | +3,396.18% | +4,573.47% | +4,573.47% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Semiconductors: +12.5%-6.6% Q3'22: +6.7% (vs Q3'21)
-
EPS growth Semiconductors: +22.5%-686.1% Q3'22: +100.2% (vs Q3'21)
-
FCF margin FCF growth · Semiconductors: +38.2%+17.7% Q3'22: +28.3% (vs Q3'21)
-
EBIT margin Semiconductors: +10.7%+0.0% Q3'22: +0.0% (vs Q3'21)
-
ROIC Semiconductors: +6.0%+0.0% Q3'22: +0.0% (vs Q3'21)
-
Share dilution Semiconductors: +0.0%+0.0% Q3'22: +171.1% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Semiconductors: -0.75×4.53× Q3'22: 4.41× (vs Q3'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
8.35B
est.
|
11.15B
est.
|
16.00B
16.00B – 16.00B
+43.5% YoY
|
23.04B
23.04B – 23.04B
+44.0% YoY
|
31.67B
31.67B – 31.67B
+37.4% YoY
|
37.18B
37.18B – 37.18B
+17.4% YoY
|
30.51B
30.51B – 30.51B
-18.0% YoY
|
| EBITDA |
1.50B
est.
|
2.01B
est.
|
2.88B
2.88B – 2.88B
+43.5% YoY
|
4.15B
4.15B – 4.15B
+44.0% YoY
|
5.70B
5.70B – 5.70B
+37.4% YoY
|
6.70B
6.70B – 6.70B
+17.4% YoY
|
5.49B
5.49B – 5.49B
-18.0% YoY
|
| EBIT |
637.27M
est.
|
850.85M
est.
|
1.22B
1.22B – 1.22B
+43.5% YoY
|
1.76B
1.76B – 1.76B
+44.0% YoY
|
2.42B
2.42B – 2.42B
+37.4% YoY
|
2.84B
2.84B – 2.84B
+17.4% YoY
|
2.33B
2.33B – 2.33B
-18.0% YoY
|
| Net Income |
25.79M
est.
|
44.14M
est.
|
64.14M
64.14M – 64.14M
+45.3% YoY
|
97.43M
97.43M – 97.43M
+51.9% YoY
|
140.87M
140.87M – 140.87M
+44.6% YoY
|
176.76M
176.76M – 176.76M
+25.5% YoY
|
149.38M
149.38M – 149.38M
-15.5% YoY
|
| SGA |
3.77B
est.
|
5.04B
est.
|
7.23B
7.23B – 7.23B
+43.5% YoY
|
10.41B
10.41B – 10.41B
+44.0% YoY
|
14.30B
14.30B – 14.30B
+37.4% YoY
|
16.79B
16.79B – 16.79B
+17.4% YoY
|
13.78B
13.78B – 13.78B
-18.0% YoY
|
| EPS |
2.26
est.
|
3.88
est.
|
5.63
5.63 – 5.63
+45.3% YoY
|
8.56
8.56 – 8.56
+51.9% YoY
|
12.37
12.37 – 12.37
+44.6% YoY
|
15.52
15.52 – 15.52
+25.5% YoY
|
13.12
13.12 – 13.12
-15.5% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | TD Global Technology Leaders Index ETF TEC.TO | 0.66% | 23.49M | 0.39% |
| 2 | TD Q Global Multifactor ETF TQGM.TO | 0.42% | 3.93M | 0.45% |
| 3 | TD U.S. Equity Index ETF TPU.TO | 0.40% | 17.43M | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jesse F. Ledger | Pres & Chief Executive Officer | 605.9K | male |
| Katina K. Loucaides | Vice President, Corporation Sec. & Gen. Counsel | 477.1K | female |
| Bernard Joseph Chiasson | Vice President of Operations & Chief Scientific Officer | 476.4K | — |
| Luigi Berardelli | Vice President of Sales & Marketing | 416.6K | male |
| Mary-Jane E. Burkett | Vice President & Chief Financial Officer | 364.1K | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MRV.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
